Correction: Endometriosis MR mimickers: T2-hypointense lesions.
Ruaux E, VanBuren WM, Nougaret S, Gavrel M, Charlot M, Grangeon F, Bolze PA, Thomassin-Naggara I, Rousset P.
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study.
Trecourt A, Bakrin N, Glehen O, Gertych W, Villeneuve L, Isaac S, Benzerdjeb N, Fontaine J, Genestie C, Dartigues P, Leroux A, Quenet F, Marchal F, Odin C, Khellaf L, Svrcek M, Thierry S, Augros M, Omar A, Devouassoux-Shisheboran M, Kepenekian V; RENAPE Group.
Imaging in pleural Mesothelioma: A review of the 16th International Conference of the International Mesothelioma Interest Group.
Armato SG 3rd, Katz SI, Frauenfelder T, Jayasekera G, Catino A, Blyth KG, Theodoro T, Rousset P, Nackaerts K, Opitz I.
CT venography for the diagnosis of postpartum venous thromboembolism: a prospective multi-center cohort study.
Revel MP, Chassagnon G, Sanchez O, Ferretti G, Millet I, Rocher L, Maitre S, Lederlin M, Ducou-le-Pointe H, Rousset P, Bennani S, Zins M, Bruneau B, Tissot V, Alison M, Canniff E, Siauve N, Vandeventer S, Le Blanche AF, Planquette B, Tsatsaris V, Coste J.
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
Azaïs H, Brochard C, Taly V, Benoit L, Ferron G, Ray-Coquard I, You B, Abadie-Lacourtoisie S, Lebreton C, Venat L, Louvet C, Favier L, Blonz C, Dohollou N, Malaurie E, Dubot C, Kurtz JE, Pujade-Lauraine E, Rouleau E, Leary A, Bats AS, Blons H, Laurent-Puig P.
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
Kamrava MR, Gonzalez-Martin A, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick C, Lorusso D, Freyer G, O’Malley DM, York W, Malinowska IA, Monk BJ.
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib.
Barnicle A, Ray-Coquard I, Rouleau E, Cadoo K, Simpkins F, Aghajanian C, Leary A, Poveda A, Lheureux S, Pujade-Lauraine E, You B, Ledermann J, Matulonis U, Gourley C, Timms KM, Lai Z, Hodgson DR, Elks CE, Dearden S, Egile C, Lao-Sirieix P, Harrington EA, Brown JS.
Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress.
Tchernonog E, Moignet A, Anota A, Bernard S, Bouguet G, Colin F, Rioufol C, Ysebaert L, Gyan E.
Attributes for a discrete-choice experiment on preferences of patients for oncology pharmacy consultations.
Damerval M, Bennani M, Rioufol C, Omrani S, Riboulet M, Etienne-Selloum N, Saint-Ghislain A, Leenhardt F, Schmitt A, Simon N, Clairet AL, Meurisse A; French Implication Expert Panel; Nerich V.
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs.
Martin T, Rioufol C, Favier B, Martelli N, Madelaine I, Chouaid C, Borget I.
Cost-effectiveness of the ONCORAL multidisciplinary programme for the management of outpatients taking oral anticancer agents at risk of drug-related event: protocol for a pragmatic randomised controlled study.
Huot L, Guerre P, Descotes G, Caffin AG, Herledan C, Ranchon F, Rioufol C.
Eliminating the need for preoperative intravenous hyperhydration: Sodium thiosulfate as nephrotoxicity prevention in HIPEC-treated patients – A retrospective analysis.
Vachez E, Kefleyesus A, Bakrin N, Ranchon F, Rioufol C, Vassal O, Al-Hadeedi O, Kepenekian V, Glehen O.